Top Story

Macrolide antibiotics fail to provide additional benefit for children with pneumonia

Macrolide antibiotics fail to provide additional benefit for children with pneumonia
November 13, 2017

For children hospitalized with community-acquired pneumonia, there is no significant difference between treatment with beta-lactam monotherapy and beta-lactam plus macrolide combination therapy concerning length of stay, intensive care admission, rehospitalization or recovery at follow-up.

“Macrolide antibiotics possess in vitro activity against Mycoplasma pneumoniae and Chlamydophila pneumoniae, and the [IDSA] guideline recommends their use when such pathogens are suspected,” Derek J. Williams, MD, MPH, from the division of hospital medicine in Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center, and colleagues wrote. “However, with few clinical studies demonstrating the effectiveness of macrolides in children, the guideline grades this recommendation as weak.”

Top stories to read on World Pneumonia Day

November 12, 2017
Although pneumonia can be prevented by immunization, good hygiene practices and adequate nutrition, it accounted for the deaths of more than 920,000 children aged…
In the Journals Plus

Outpatient prescribing drives unnecessary antibiotic use for CAP

November 10, 2017
More than 70% of patients hospitalized with community-acquired pneumonia in the United States received antibiotic treatment longer than recommended, according to recent…
In the JournalsPerspective

Readmission decline may be linked to lower mortality in acute MI, HF, pneumonia

July 18, 2017
The decrease in 30-day readmissions in Medicare fee-for-service beneficiaries with acute MI, HF and pneumonia was associated with a decrease in 30-day mortality rates…
More Headlines »
CME Article

Diffuse Lung Disease in Children

Pediatric Annals, December 2010, Volume 39 Issue 12
A 3-month-old is brought in by her mother for evaluation because she said she believes the baby breathes faster than…
More »
Meeting News

VIDEO: Gefitinib may ‘change the paradigm’ to treat lung cancer

August 10, 2017
More »